Metropolis Healthcare has released its audited financial results for the quarter and financial year ended March 31, 2026. The company announced a minor administrative correction regarding the Profit attributable to owners for the comparative quarter ended March 31, 2025. This revision does not impact figures for the current financial year. Metropolis continues to show robust growth, with a strong focus on pathology services and strategic expansion through recent business acquisitions.
Financial Performance Overview
For the financial year ended March 31, 2026, Metropolis Healthcare reported a Revenue from operations of ₹1,64,584.59 lakh on a consolidated basis, compared to ₹1,33,120.28 lakh in the previous year. The company’s Profit for the year (consolidated) reached ₹19,118.20 lakh, reflecting a steady upward trajectory in its financial performance.
Strategic Acquisitions and Growth
During the fiscal year, Metropolis aggressively expanded its footprint through strategic business acquisitions. Notable transactions include the acquisition of DAPIC Metropolis Healthcare Private Limited, Scientific Metropolis Pathology Private Limited, and pathology laboratories in Kolhapur. These strategic moves, aimed at strengthening the company’s pathology service segment, represent significant investments in future growth and service penetration.
Operational Highlights
The company maintains a strong balance sheet with Total Equity standing at ₹1,52,455.50 lakh as of March 31, 2026. The board has also demonstrated commitment to shareholder value, declaring an Interim Dividend of ₹1 per equity share on 20,73,31,968 equity shares, following a successful 3:1 bonus share issuance earlier in the year. Additionally, the company continues to manage its workforce compensation in alignment with the newly notified Labour Codes, ensuring compliance and operational efficiency.
Administrative Update
The management has addressed an inadvertent error in the disclosure of ‘Profit attributable to owners of the Company’ for the quarter ended March 31, 2025. This administrative adjustment is confirmed to be non-material and has zero impact on the current financial year’s results. All other figures remain consistent with those previously reported.
Source: BSE
